content: <HTML>
  <HEAD>
  <TITLE>
  </TITLE>
  </HEAD>
  <BODY>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SECURITIES
  AND EXCHANGE COMMISSION</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>WASHINGTON,
  D.C. 20549</FONT></H1>
  
  <HR SIZE=1 NOSHADE WIDTH=15% ALIGN=CENTER>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>FORM 8-K</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT
  REPORT</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PURSUANT TO
  SECTION 13 OR 15(d) OF THE</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SECURITIES
  EXCHANGE ACT OF 1934</FONT></H1>
  
                                   Date of Report (Date of earliest event reported): September 20, 2001
  
  
                                                                SCIOS, INC.
  <HR SIZE=1 NOSHADE WIDTH=15% ALIGN=CENTER>
  
                                            (Exact Name of Registrant as Specified in Charter)
  
  
                Delaware__                                0-11749                               95-3701481
   --------------------------------------     ---------------------------------         ------------------
      (State or Other Jurisdiction of             (Commission File Number)         (I.R.S. Employer Identification No.)
               Incorporation)
  
  
                                        820 West Maude Avenue, Sunnyvale, CA 94086
                           -------------------------------------------------------
                                   (Address of Principal Executive Offices) (Zip Code)
                                                  (408) 616-8200_
                       ------------------------------------------
                                  (Registrant's telephone number, including area code)
  
                                                        N/A
                             ------------------------------
                              (Former Name or Former Address, if Changed Since Last Report)
  
  
  
  
  
  
  
  <PAGE>
  
  
  <H2 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 5. Other
  Events.</FONT></H2>
  
  The press release attached as an exhibit in Item 7 to this Current Report on Form 8-K and the contents contained therein are
  incorporated by reference herein.
  
  
  
  Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)               Exhibits
  
                    The following exhibits are filed as part of this Report:
  
                    No.      Exhibit
                    ---      -------
                    99.1     Press Release dated September 20, 2001
  
  
  
  
  
  <PAGE>
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES</FONT></H1>
  
  <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
  to the requirements of the Securities Exchange Act of 1934, the registrant has
  duly caused this report to be signed on its behalf by the undersigned hereunto
  duly authorized. </FONT></P>
  
                                              SCIOS, INC.
  
  
                                              By:      /s/  David W. Gryska                                                     ---------------------------------
                                                       David W. Gryska
                                                       Senior Vice President and Chief Financial Officer
  
  
  Date:  September 20, 2001
  
  
  
  <PAGE>
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT INDEX</FONT></H1>
  
  No.      Exhibit
  ---      -------
  99.1     Press Release dated September 20, 2001
  
  
  <PAGE>
  
  
  
                                                                                                           Exhibit 99.1
                                                                                                           ------------
  
  Contact:
  --------
  Wendy Carhart, Scios Inc. (408) 616 8325 (investors)
  Jim Weiss, Weisscomm (415) 389-5055 (media)
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Scios
  Announces $10 Million Stock Repurchase Plan</FONT></H1>
  
  SUNNYVALE, Calif., Sept. 20, 2001 - Scios Inc. (Nasdaq: SCIO) announced today that, effective immediately, its Board of Directors has
  authorized the repurchase of up to $10 million of Scios common stock.  The repurchases are to be made through open-market
  transactions at the discretion of management and as market conditions warrant.
  "We have confidence in Scios' short-term prospects with the marketing of Natrecor and our long-term strength and value," commented
  Richard B. Brewer, Scios' Chief Executive Officer.  "At current prices, we believe Scios represents an excellent investment
  opportunity."
  At June 30, 2001, Scios had $164 million in cash and marketable securities.
  Scios Inc.
  Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease.  The Company's
  disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify
  novel targets and rationally design small molecule compounds for large markets with unmet medical needs.
  
  <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This news release contains
  forward-looking statements within the meaning of Section 27A of the Securities
  Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally
  identify such forward-looking statements using words like &#147;believe,&#148;
  &#147;intend,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;should,&#148;
  &#147;plan,&#148; &#147;project,&#148; &#147;contemplate,&#148;
  &#147;anticipate&#148; or similar statements. Statements that are not historical
  facts are forward-looking statements based on current assumptions that involve
  risks and uncertainties. These risks and uncertainties may include the sales
  penetration and success of Natrecor, as well as other risks detailed from time
  to time in the reports filed by Scios with the SEC, including the Company&#146;s
  quarterly reports and annual report on Form 10-K. Actual results, performance or
  achievements of Scios may differ significantly from those described in these
  forward-looking statements. Scios disclaims any intention or obligation to
  update or revise any financial projections or forward-looking statements,
  whether as a result of new information, future events or otherwise. </FONT></P>
  </BODY>
  </HTML>
                                                                   # # #
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "k8sciosinc092001.htm", "description": "SCIOS INC REPURCHASE", "secsgml_size_bytes": 6548}]
metadata_filer: {"company-data": {"conformed-name": "SCIOS INC", "cik": "0000726512", "assigned-sic": "2834", "irs-number": "953701481", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11749", "film-number": "1741305"}, "business-address": {"street1": "820 W MAUDE AVE", "city": "SUNNYVALE", "state": "CA", "zip": "94086", "phone": "4086168200"}, "mail-address": {"street1": "820 W MAUDE AVENUE", "city": "SUNNYVALE", "state": "CA", "zip": "94085"}, "former-company": [{"former-conformed-name": "CALIFORNIA BIOTECHNOLOGY INC", "date-changed": "19920302"}, {"former-conformed-name": "SCIOS NOVA INC", "date-changed": "19930423"}]}
text: SECURITIES
  AND EXCHANGE COMMISSION
  WASHINGTON,
  D.C. 20549
  FORM 8-K
  CURRENT
  REPORT
  PURSUANT TO
  SECTION 13 OR 15(d) OF THE
  SECURITIES
  EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported): September 20, 2001
  
                                                                SCIOS, INC.
  (Exact Name of Registrant as Specified in Charter)
  
                Delaware__                                0-11749                               95-3701481
   --------------------------------------     ---------------------------------         ------------------
      (State or Other Jurisdiction of             (Commission File Number)         (I.R.S. Employer Identification No.)
               Incorporation)
  
                                        820 West Maude Avenue, Sunnyvale, CA 94086
                           -------------------------------------------------------
                                   (Address of Principal Executive Offices) (Zip Code)
                                                  (408) 616-8200_
                       ------------------------------------------
                                  (Registrant's telephone number, including area code)
  
                                                        N/A
                             ------------------------------
                              (Former Name or Former Address, if Changed Since Last Report)
  Item 5. Other
  Events.
  The press release attached as an exhibit in Item 7 to this Current Report on Form 8-K and the contents contained therein are
  incorporated by reference herein.
  
  Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)               Exhibits
  
                    The following exhibits are filed as part of this Report:
  
                    No.      Exhibit
                    ---      -------
                    99.1     Press Release dated September 20, 2001
  SIGNATURES
  Pursuant
  to the requirements of the Securities Exchange Act of 1934, the registrant has
  duly caused this report to be signed on its behalf by the undersigned hereunto
  duly authorized.
  SCIOS, INC.
  
                                              By:      /s/  David W. Gryska                                                     ---------------------------------
                                                       David W. Gryska
                                                       Senior Vice President and Chief Financial Officer
  
  Date:  September 20, 2001
  EXHIBIT INDEX
  No.      Exhibit
  ---      -------
  99.1     Press Release dated September 20, 2001
  Exhibit 99.1
                                                                                                           ------------
  
  Contact:
  --------
  Wendy Carhart, Scios Inc. (408) 616 8325 (investors)
  Jim Weiss, Weisscomm (415) 389-5055 (media)
  Scios
  Announces $10 Million Stock Repurchase Plan
  SUNNYVALE, Calif., Sept. 20, 2001 - Scios Inc. (Nasdaq: SCIO) announced today that, effective immediately, its Board of Directors has
  authorized the repurchase of up to $10 million of Scios common stock.  The repurchases are to be made through open-market
  transactions at the discretion of management and as market conditions warrant.
  "We have confidence in Scios' short-term prospects with the marketing of Natrecor and our long-term strength and value," commented
  Richard B. Brewer, Scios' Chief Executive Officer.  "At current prices, we believe Scios represents an excellent investment
  opportunity."
  At June 30, 2001, Scios had $164 million in cash and marketable securities.
  Scios Inc.
  Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease.  The Company's
  disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify
  novel targets and rationally design small molecule compounds for large markets with unmet medical needs.
  This news release contains
  forward-looking statements within the meaning of Section 27A of the Securities
  Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally
  identify such forward-looking statements using words like "believe,"
  "intend," "expect," "may," "should,"
  "plan," "project," "contemplate,"
  "anticipate" or similar statements. Statements that are not historical
  facts are forward-looking statements based on current assumptions that involve
  risks and uncertainties. These risks and uncertainties may include the sales
  penetration and success of Natrecor, as well as other risks detailed from time
  to time in the reports filed by Scios with the SEC, including the Company's
  quarterly reports and annual report on Form 10-K. Actual results, performance or
  achievements of Scios may differ significantly from those described in these
  forward-looking statements. Scios disclaims any intention or obligation to
  update or revise any financial projections or forward-looking statements,
  whether as a result of new information, future events or otherwise.
  # # #